title: miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.
abstract: Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype that lacks effective targeted therapies. The epithelial-to-mesenchymal transition (EMT) is a key contributor in the metastatic process. In this study, we found that miR-655 was down-regulated in TNBC, and its expression levels were associated with molecular-based classification and lymph node metastasis in breast cancer. These findings led us to hypothesize that miR-655 overexpression may inhibit EMT and its associated traits of TNBC. Ectopic expression of miR-655 not only induced the up-regulation of cytokeratin and decreased vimentin expression but also suppressed migration and invasion of mesenchymal-like cancer cells accompanied by a morphological shift towards the epithelial phenotype. In addition, we found that miR-655 was negatively correlated with Prrx1 in cell lines and clinical samples. Overexpression of miR-655 significantly suppressed Prrx1, as demonstrated by Prrx1 3'-untranslated region luciferase report assay. Our study demonstrated that miR-655 inhibits the acquisition of the EMT phenotype in TNBC by down-regulating Prrx1, thereby inhibiting cell migration and invasion during cancer progression.
authors.affiliation: Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
authors.forename: Zhi-Dong
authors.initials: ZD
authors.lastname: Lv
authors.affiliation: Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Kong
authors.affiliation: Central Laboratory of Molecular Biology, The Affiliated Hospital of Qingdao University, Qingdao, China.
authors.forename: Xiang-Ping
authors.initials: XP
authors.lastname: Liu
authors.affiliation: Cerebrovascular Disease Research Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
authors.forename: Li-Ying
authors.initials: LY
authors.lastname: Jin
authors.affiliation: Department of Pediatric Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Dong
authors.affiliation: Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
authors.forename: Fu-Nian
authors.initials: FN
authors.lastname: Li
authors.affiliation: Department of Breast Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China.
authors.forename: Hai-Bo
authors.initials: HB
authors.lastname: Wang
mesh_terms: D020413:3' Untranslated Regions; D000328:Adult; D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement; D058750:Epithelial-Mesenchymal Transition / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D017930:Genes, Reporter; D018398:Homeodomain Proteins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007633:Keratins / Q000235:genetics / Q000378:metabolism; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008207:Lymphatic Metastasis; D051379:Mice; D008819:Mice, Nude; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011485:Protein Binding; D015398:Signal Transduction; D014746:Vimentin / Q000235:genetics / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D020413:3' Untranslated Regions; D018398:Homeodomain Proteins; C585264:MIRN655 microRNA, human; D035683:MicroRNAs; C082157:PRRX1 protein, human; D014746:Vimentin; D007633:Keratins; D008156:Luciferases
keywords: Prrx1; epithelial-to-mesenchymal transition; miR-655; triple-negative breast cancer
references.citation: Oncotarget. 2015 Jun 10;6(16):14545-55
references.pmid: 26036630
references.citation: J Pathol. 2015 Aug;236(4):505-16
references.pmid: 25925492
references.citation: Hepatogastroenterology. 2014 Jun;61(132):1082-9
references.pmid: 26158169
references.citation: BMC Genomics. 2015;16:529
references.pmid: 26187636
references.citation: Mol Cancer Ther. 2014 Feb;13(2):444-53
references.pmid: 24258346
references.citation: Oncotarget. 2014 Jun 30;5(12):4144-4153
references.pmid: 24980827
references.citation: Breast Cancer Res Treat. 2015 Jul;152(1):183-91
references.pmid: 26062749
references.citation: Ann Med Health Sci Res. 2014 Nov;4(6):933-7
references.pmid: 25506489
references.citation: PLoS One. 2013;8(5):e62757
references.pmid: 23690952
references.citation: Cancer Lett. 2014 Aug 28;351(1):151-61
references.pmid: 24880079
references.citation: Breast Cancer Res Treat. 2014 Nov;148(1):211-20
references.pmid: 25281216
references.citation: Histochem Cell Biol. 2012 Sep;138(3):477-88
references.pmid: 22610129
references.citation: Oncotarget. 2015 Feb 28;6(6):3737-51
references.pmid: 25686832
references.citation: Clin Exp Metastasis. 2015 Jan;32(1):83-98
references.pmid: 25579665
references.citation: Breast Cancer Res. 2015;17:83
references.pmid: 26070602
references.citation: Br J Cancer. 2015 Jul 14;113(2):290-8
references.pmid: 26057454
references.citation: Cancer Lett. 2015 Sep 28;366(1):1-10
references.pmid: 26099173
references.citation: Nature. 2013 Jan 24;493(7433):487-8
references.pmid: 23344357
references.citation: Am J Pathol. 2014 Aug;184(8):2342-54
references.pmid: 24946010
references.citation: Breast Cancer Res. 2015;17:85
references.pmid: 26080807
references.citation: Br J Cancer. 2013 Jul 23;109(2):307-11
references.pmid: 23807160
references.citation: Cancer Res. 2015 Jul 1;75(13):2594-9
references.pmid: 26069247
references.citation: Oncotarget. 2014 Aug 15;5(15):6375-86
references.pmid: 25071007
references.citation: Toxicol Res. 2015 Jun;31(2):151-6
references.pmid: 26191381
references.citation: PLoS One. 2014;9(4):e93917
references.pmid: 24705396
references.citation: Genes Cancer. 2015 May;6(5-6):281-7
references.pmid: 26124926
references.citation: Oncotarget. 2015 Jun 20;6(17):15222-34
references.pmid: 25945841
references.citation: BMC Cancer. 2015;15:499
references.pmid: 26141719
references.citation: Oncol Rep. 2013 Jan;29(1):219-25
references.pmid: 23129177
references.citation: Hepatogastroenterology. 2014 Nov-Dec;61(136):2416-20
references.pmid: 25699394
references.citation: Oncotarget. 2015 Apr 20;6(11):8875-89
references.pmid: 25823925
references.citation: Cancer Cell. 2012 Dec 11;22(6):709-24
references.pmid: 23201163